Cited by 22Sarcoidosis and Beryllium Toxicity ResearchViral Infections and Immunology ResearchVasculitis and related conditions

Serum Anti-Heart and Anti-Intercalated Disk Autoantibodies: Novel Autoimmune Markers in Cardiac Sarcoidosis

Open access
Caforio, Alida L. P., Baritussio, Anna, Marcolongo, Renzo, Cheng, Chun-Yan, Pontara, Elena, Bison, Elisa, Cattini, Maria Grazia, Gallo, Nicoletta +5 more·2021·Journal of Clinical Medicine

Abstract

Background: Sarcoidosis is an immune-mediated disease. Cardiac involvement, a granulomatous form of myocarditis, is under-recognized and prognostically relevant. Anti-heart autoantibodies (AHAs) and anti-intercalated disk autoantibodies (AIDAs) are autoimmune markers in nonsarcoidosis myocarditis forms. Objective: The aim was to assess serum AHAs and AIDAs as autoimmune markers in cardiac sarcoidosis. Methods: This is a cross-sectional study on AHA and AIDA frequency in: 29 patients (aged 46 ± 12, 20 male) with biopsy-proven extracardiac sarcoidosis and biopsy-proven or clinically suspected and confirmed by 18-fluorodeoxyglucose positron emission tomography and/or cardiovascular magnetic resonance (CMR) cardiac involvement; 30 patients (aged 44 ± 11, 12 male) with biopsy-proven extracardiac sarcoidosis without cardiac involvement (no cardiac symptoms, normal 12-lead electrocardiogram, echocardiography and CMR), and control patients with noninflammatory cardiac disease (NICD) (n = 160), ischemic heart failure (IHF) (n = 141) and normal blood donors (NBDs) (n = 270). Sarcoidosis patients were recruited in two recruiting tertiary centers in the USA and Italy. AHAs and AIDAs were detected by indirect immunofluorescence on the human myocardium and skeletal muscle. Results: AHA and AIDA frequencies were higher in sarcoidosis with cardiac involvement (86%; 62%) than in sarcoidosis without cardiac involvement (0%; 0%), NICD (8%; 4%), IHF (7%; 2%) and NBD (9%; 0%) (p = 0.0001; p = 0.0001, respectively). Sensitivity and specificity for cardiac sarcoidosis were 86% and 92% for positive AHAs and 62% and 98% for positive AIDAs, respectively. AIDAs in cardiac sarcoidosis were associated with a higher number of involved organs (p = 0.04). Conclusions: Serum AHAs and AIDAs provide novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm10112476

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Anti-heart autoantibodies and anti-intercalated disk autoantibodies are present exclusively in patients with cardiac sarcoidosis and absent in those with sarcoidosis lacking cardiac involvement.

    “findings by Caforio et al 218 indicate the presence of anti-heart autoantibodies and anti-intercalated disk autoantibodies exclusively in patients with cardiac sarcoidosis, absent in those with sarcoidosis lacking cardiac involvement.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [218]

    Results §3.2 (page unavailable) found AHAs in 86% and AIDAs in 62% of the cardiac-sarcoidosis group, versus 0% for both in the group without cardiac involvement. The unqualified word “exclusively” overstates the finding: both antibodies also occurred in some non-sarcoidosis control groups, and neither was present in every cardiac-sarcoidosis patient. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • In earlier studies, autoantibodies targeting heart antigens have been identified in both myocarditis patients and animal models, regardless of the underlying cause-viral infections or existing autoimmune conditions.

    “In earlier studies, autoantibodies targeting heart antigens have been identified in both myocarditis patients and animal models, regardless of the underlying cause-viral infections or existing autoimmune conditions. 15-18,57,189,190,218”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [218]

    The Introduction identifies anti-heart autoantibodies as markers in human myocarditis, and Discussion §4.3 describes cardiac myosin as an autoantibody target in several forms of myocarditis and in postinfectious immune-mediated heart diseases. The paper does not report findings in animal models or establish the claim specifically for viral infections, so those parts are unsupported by this source. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Autoimmune responses against the heart may play a role in the onset and progress of cardiac sarcoidosis.

    “This suggests a potential role of autoimmune responses against the heart in the onset and progress of cardiac sarcoidosis.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [218]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Caforio, A. L. P., Baritussio, A., Marcolongo, R., Cheng, C.-Y., Pontara, E., Bison, E., Cattini, M. G., Gallo, N., Plebani, M., Iliceto, S., Semenzato, G., Maier, L., & Hamzeh, N.
Affiliations
  • University of Padua (IT)
  • National Jewish Health (US)
  • University of Iowa (US)
Corresponding author
Caforio, Alida L. P.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2021-06-02
Volume
10
Issue
11
Pages
2476
ISSN
2077-0383 (ISSN-L)
OpenAlex
W3166428737
Cited by
22
References
39
Citations by year
2026: 6 · 2025: 1 · 2024: 7 · 2023: 2 · 2022: 4 · 2021: 2
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
Funders
Università degli Studi di Padova (BIRD2019)
Topics
  • Health Sciences › Medicine › Physiology › Sarcoidosis and Beryllium Toxicity Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
Keywords
cardiac sarcoidosis, autoimmune markers, myocarditis, granulomatous myocarditis, extracardiac sarcoidosis, sensitivity and specificity, non-invasive diagnosis, ischemic heart failure, organ involvement

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review